5-chloro-7-(N-2,2,2-trifluoroethylamino)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine | 214633-89-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-chloro-7-(N-2,2,2-trifluoroethylamino)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine
• 英文别名: 5-chloro-6-(2,4,6-trifluorophenyl)-N-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine；5-chloro-N-(2,2,2-trifluoroethyl)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine；5-chloro-7-(2,2,2-tri-fluoroethylamino)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine；[5-chloro-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl](2,2,2-trifluoroethyl)amine；5-chloro-6-(2,4,6-trifluorophenyl)-N-(2,2,2-trifluoroethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine；5-chloro-7-(2,2,2-trifluoroethylamino)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]-pyrimidine
• CAS: 214633-89-3
• 化学式: C₁₃H₆ClF₆N₅
• 分子量: 381.668
• InChiKey: FEOXAMHBHGUNHP-UHFFFAOYSA-N

物化性质

• 熔点：
  168-170 °C
• 密度：
  1.75±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  5-chloro-7-(N-2,2,2-trifluoroethylamino)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine 在 sodium hydride 作用下， 以 二甲基亚砜 为溶剂， 生成 4-chloro-6-[(2,2,2-trifluoroethyl)amino]-5-(2,4,6-trifluorophenyl)pyrimidin-2-yl(ethyl)cyanamide
  参考文献：
  名称：

  2-Cyanoaminopyrimidines as a class of antitumor agents that promote tubulin polymerization

  摘要：

  A series of 4-chloro-2-cyanoamino-6-fluoroalkylamino-5-phenylpyrimidines was prepared as a result of our efforts to modify a series of [1,2,4]triazolo[1,5-a]pyrimidines that proved to be potent anticancer agents with a unique mechanism of tubulin inhibition. On the cyanoamino nitrogen, a methyl group is optimal for activity among alkyl groups introduced. The structure-activity relationship for the rest of the molecule resembles that of [1,2,4]triazolo[1,5-a]pyrimidines. A lead compound (5) retained in vitro potency compared with TTI-237. In the mechanism of action studies, it behaved in the same manner as TTI-237. In addition, it is also capable of overcoming multidrug resistance due to P-gp. These findings strongly suggest that this series of 2-cyanoaminopyrimidines binds at the same site and in the same binding mode as TTI-237. Further modifications of the 2-cyanoamino group are underway. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.070
• 作为产物：
  描述：

  2,4,6-三氟苯基丙二酸二乙酯 在 三正丁胺 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 5-chloro-7-(N-2,2,2-trifluoroethylamino)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES
  [FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION POUR LE TRAITEMENT DE TAUOPATHIES NEURODÉGÉNÉRATIVES

  摘要：

  公开号：

  WO2014047257A3

文献信息

• 5-arylpyrimidines as anticancer agents
  申请人：Zhang Nan

  公开号：US20050075357A1

  公开（公告）日：2005-04-07

  This invention relates to certain 5-arylpyrimidine compounds or a pharmaceutically acceptable salt thereof, and compositions containing said compounds or a pharmaceutically acceptable salt thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

  这项发明涉及某些5-芳基嘧啶化合物或其药用盐，以及含有所述化合物或其药用盐的组合物，其中所述化合物是抗癌剂，可用于治疗哺乳动物的癌症。该发明还涉及一种治疗或抑制哺乳动物体内癌细胞和相关疾病生长的方法，并进一步提供了一种治疗或预防表达多药耐药性（MDR）或因MDR耐药的癌症肿瘤的方法，该方法包括向所述哺乳动物体内施用所述化合物或其药用盐的有效量。更具体地，本发明涉及通过促进微管聚合来治疗或抑制哺乳动物体内癌细胞和相关疾病的方法，该方法包括向所述哺乳动物体内施用所述化合物及其药用盐的有效量。
• Use of Azolopyrimidines for Controlling Phytopathogenic Harmful Fungi
  申请人：Dietz Jochen

  公开号：US20100056371A1

  公开（公告）日：2010-03-04

  Azolopyrimidines of the formula I in which the symbols are each defined as specified in the description are suitable for controlling phytopathogenic harmful fungi.

  式(I)中的符号如说明书所述，适用于控制植物病原真菌。
• HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES
  申请人：THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

  公开号：US20150224105A1

  公开（公告）日：2015-08-13

  The present invention is directed to triazolopyrimidine, phenylpyrimidine, pyridopyridazine, and pyridotriazine compounds which are microtubule-stabilizing compounds and their use in the treatment of neurodegenerative disorders, in particular, tauopathies, such as for example, Alzheimer's disease, frontotemporal lobar degeneration, Pick's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration. In addition, the compounds of the invention may be useful for other diseases where tau pathology is a comorbidity or where microtubule function is compromised, for example, schizophrenia, Parkinson's disease (PD), PD with dementia, Lewy body disease with dementia, and amyotrophic lateral sclerosis.

  本发明涉及三唑并嘧啶、苯基嘧啶、吡啶并吡嗪和吡啶并三嗪类化合物，它们是微管稳定剂化合物，以及它们在治疗神经退行性疾病中的应用，特别是tau病理学，例如阿尔茨海默病、额颞叶变性、皮克氏病、进展性上皮核瘤和皮质基底节变性。此外，本发明中的化合物也可能对其他tau病理学是共病或微管功能受损的疾病有用，例如精神分裂症、帕金森病（PD）、带有痴呆的PD、带有痴呆的Lewy体病和肌萎缩侧索硬化症。
• USE OF HYDROPHOBIN AS A SPREADING AGENT
  申请人：Barg Heiko

  公开号：US20110312497A1

  公开（公告）日：2011-12-22

  The present invention relates to the use of hydrophobin as a spreading agent, in particular in cosmetic or pharmaceutical compositions. The invention further relates to compositions for treating surfaces, in particular cosmetic or pharmaceutical compositions for topical use, that contain hydrophobin as a spreading agent.

  本发明涉及在化妆品或药物组合物中使用亲水素作为扩散剂。本发明还涉及含有亲水素作为扩散剂的用于处理表面的组合物，特别是用于局部使用的化妆品或药物组合物。
• Wirkstoffzusammensetzung die wenigstens ein stickstoffatomhaltiges, hyperverzweigtes Polymer enthält
  申请人：BASF SE

  公开号：EP2308460A1

  公开（公告）日：2011-04-13

  Die vorliegende Erfindung betrifft eine Wirk- oder Effektstoffzusammensetzung, die wenigstens einen in Wasser schwerlöslichen Wirk- oder Effektstoff und wenigstens ein hyperverzweigtes Polymer enthält.

  本发明涉及一种活性成分或效应剂组合物，其中包含至少一种难溶于水的活性成分或效应剂和至少一种超支化聚合物。